Search

Memorial Sloan Kettering Cancer Center (MSK) announced that pediatric oncologist Richard Gilbertson, MBBS, PhD, of Cancer Research UK Cambridge Institute, has been named the 2022 recipient of The Society of Memorial Sloan Kettering Prize.

When Memorial Sloan Kettering Cancer Center (MSK) opened its doors along Commack Road in 2002, eastern Long Islanders no longer needed to navigate congested roadways and train lines bound for Manhattan to receive personalized cancer care. Today, more than 14 years later, MSK is reinforcing its commitment to the local community in the form of a 38,000-plus-square-foot addition complete with enhancements to both clinical programs and physical spaces.

Memorial Sloan Kettering announced the appointment of Pereira & O’Dell in New York as its creative agency of record and Media Storm as its media agency of record.

MSK physicians and scientists are involved in notable research to be presented during the virtual meeting.

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

Antibody-drug conjugates and checkpoint inhibitors show promise as new therapies for bladder cancer.

Learn the most frequently asked questions about immunotherapy, a form of cancer treatment that uses the body's own immune system to overpower cancer cells. Learn who it can help, how it works, and how experts at MSK are finding ways to make it benefit more people, including new combinations with other cancer treatments like chemotherapy, surgery, radiation and more.

After receiving a stem cell transplant for multiple myeloma, John Savarese developed graft-versus-host disease (GVHD). MSK’s specialized GVHD clinic got him back to feeling like himself again.